Overview

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine if liquid alpha1-proteinase inhibitor (human) (liquid alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus placebo plus SMT in hospitalized participants with COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

Grifols Therapeutics LLC

Treatments:

Alpha 1-Antitrypsin
Protease Inhibitors